Search Results

You are looking at 51 - 60 of 299 items for :

Clear All
Full access

Tim Luetkens, Sabarinath Venniyil Radhakrishnan, Sandra D. Scherer, Patricia Davis, Erica R. Vander Mause, Michael L. Olson, Sara Yousef, Jens Panse, Yasmina Abdiche, K. David Li, Rodney R. Miles, William Matsui, Alana L. Welm and Djordje Atanackovic

Background: The SLAM receptor CD229/LY9 is strongly expressed on multiple myeloma (MM) cells and is required for their growth, rendering it a potential target for the treatment of MM. Methods: We used antibody phage display to develop the first

Full access

Plasma cell neoplasms are diseases in which abnormal plasma cells or myeloma cells form tumors in the bones or soft tissues of the body. At the NCCN 2019 Annual Congress: Hematologic Malignancies, a panel of experts identified clinical challenges

Full access

Rodger J. Winn

References 1 Singhal S Mehta J Desikan R . Antitumor activity of thalidomide in refractory multiple myeloma . N Engl J Med 1999 ; 341 : 1565 - 1571 . 2 Richardson PG Barlogie B Bertenson J . A Phase 2 study of bortezomib

Full access

Suneel D. Kamath, Sheetal M. Kircher and Al B. Benson III

funded in proportion to their incidences. Multiple myeloma appeared to be proportionally funded, whereas gastrointestinal cancers (colorectal, pancreatic, and liver and bile duct), gynecologic cancers (ovarian, endometrial, and cervical), lung cancer

Full access

Nicolas C. Issa and Lindsey R. Baden

-old man with multiple myeloma 10 months after allogeneic hematopoietic cell transplantation who presented with fevers, cough, headaches, and myalgia. He had received the trivalent influenza vaccine 1 month before admission (pandemic 2009 H1N1 vaccine was

Full access

Antonio Palumbo and Roberto Mina

Multiple myeloma is a malignant neoplasm accounting for 1% of all cancers and 10% of hematologic neoplasms. Its incidence increases with age: the median age at diagnosis is 70 years, with only 37% of patients younger than 65 years, 26% between the

Full access

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman and Matthew R. Smith

guidelines in oncology: multiple myeloma, v.2.2009 . Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf . Accessed May 21, 2009 . 8 Batson O . The role of vertebral veins in metastatic processes . Ann Intern Med

Full access

Luke Arney, Ryan Leib, Louise Schneider, Cori Kostick, Kerry Kilbridge, Ramin Khorasani, Oreofe Odejide and Lindsay C. Carter

treatment. For example, in a study of 3,831 older adults diagnosed with myeloma in the United States, the median time between the first myeloma-related symptom and diagnosis was 99 days (Friese CR, Leukemia & Lymphoma 2009). Such delays are associated with

Full access

Tanya M. Wildes, Derek L. Stirewalt, Bruno Medeiros and Arti Hurria

, and accumulating DNA damage. 8 These changes may underlie clinical differences in hematopoietic cell mobilization between older and younger patients. Older patients with myeloma tend to mobilize fewer total progenitor or CD34 + cells/kg, and require

Full access

Donald A. Podoloff, Douglas W. Ball, Edgar Ben-Josef, Al B. Benson III, Steven J. Cohen, R. Edward Coleman, Dominique Delbeke, Maria Ho, David H. Ilson, Gregory P. Kalemkerian, Richard J. Lee, Jay S. Loeffler, Homer A. Macapinlac, Robert J. Morgan Jr., Barry Alan Siegel, Seema Singhal, Douglas S. Tyler and Richard J. Wong

. Available at: http://www.cms.hhs.gov/determinationprocess/downloads/id54TA.pdf . Accessed February 24, 2009 . 97 Schirrmeister H Bommer M Buck AK . Initial results in the assessment of multiple myeloma using 18F-FDG PET . Eur J Nucl Med Mol